Abstract library

12 results for "Antonuzzo".
#1421 Oxaliplatin-based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors
Introduction: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: Oxaliplatin, NETs
#888 Capecitabine (Cp) and Somatostatine Analog (SSA) Suitable Treatment for Progressing G1-G2 Neuroendocrine Tumors (WD NET)
Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
Keywords: capecitabine
#891 Metastatic G1-G2 Neuroendocrine Tumors (WDNET) Treated with Sequences of Different Somatostatine Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): A Single Center Experience
Introduction: PROMID and CLARINET trials demonstrate an improvement in PFS of SSA v. placebo in WDNET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Riccardo Marconcini
#892 Sunitinib in Gastroeneteropancreatic Neuroendocrine Tumor (GEP-NET) after Failure of Previous Treatments, Including Everolimus: A Series of Five Clinical Cases
Introduction: In a recent phase III study, Sunitinib has shown significant improvement of progression-free survival in patients with pancreatic NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib, everolimus
#1110 Chemotherapy with Capecitabine plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Neoplasms (NENs): An Italian Multicenter Retrospective Analysis
Introduction: A combination of capecitabine (CAP) and temozolomide (TEM) has been successfully used as first-line treatment in pancreatic neuroendocrine neoplasms (pNENs).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: NEN, NET, chemotherapy
#1120 Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET
Introduction: Oxaliplatine plus fluoropirimidine and capecitabine treatment alone are considered investigational treatments in well-differentiated (WD) NET
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
#1368 Everolimus in Pancreatic Neuroendocrine Carcinomas G3
Introduction: Neuroendocrine Carcinomas (NEC) G3 are heterogeneous diseases with different behaviors, basing on tumor morphology and Ki67 value. Platinum-based chemotherapy is considered the standard treatment in these pts. However, tumors with well-moderately differentiated morphology (NET G3), with Ki67 < 55% may be considered a separate entity in terms of prognosis and therapeutic options
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Francesco Panzuto
#1401 Everolimus (EV) Plus Somatostatin Analog (SSA) Administered Before or After Chemotherapy (CT) or PRRT in Advanced G1-G2 Neuroendocrine Tumor (NET): A Single Center Experience
Introduction: In metastatic NET G1-G2 progressed after SSA, many treatment are appropriated including EV, CT and PRRT. However, there are no studies guiding the appropriate sequence of treatments.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: everolimus SSA
#1477 Neuroendocrine Tumors of the Biliary Tract: A Retrospective, Observational Multicenter Study
Introduction: Neuroendocrine tumors of the biliary tract (BTNETs) constitute a heterogeneous group of neoplasms. Because of their rarity, the clinical behavior is unclear.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Maria Pia Brizzi
#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.